Company Growth (employees)
Sucampo Pharmaceuticals was founded in 1996 and is headquartered in Rockville, US
Sucampo Pharmaceuticals Office Locations
Sucampo Pharmaceuticals has offices in Rockville, Milton, Zug, Kita Ward and in 3 other locations
Rockville, US (HQ)
550 805 King Farm Blvd
Sanda Shi, JP
4 1 Techno Park
Chuo Ward, JP
Kobe Hybrid Business Center, 3rd Floor 6 7 6 Minatojima Minamimachi, Chuo Ku, Kobe City
Chiyoda, JP
Nbf Hibiya Building, 10th Floor 1 1 7 Uchisaiwaicho
Kita Ward, JP
Nishiumeda Mid Building, 4th Floor 2 2 16 Sonezakishinchi
Zug, CH
22 Baarerstrasse
Sucampo Pharmaceuticals Data and Metrics
Sucampo Pharmaceuticals Financial Metrics
Sucampo Pharmaceuticals's revenue was reported to be $230.1 m in FY, 2016 which is a 50% increase from the previous period.
USD
Revenue (FY, 2016) | 230.1 m |
Revenue growth (FY, 2015 - FY, 2016), % | 50% |
Gross profit (FY, 2016) | 154.1 m |
Gross profit margin (FY, 2016), % | 67% |
Net income (FY, 2016) | 18.5 m |
EBIT (FY, 2016) | 53.9 m |
Market capitalization (21-Jul-2017) | 680.1 m |
Cash (31-Dec-2016) | 198.3 m |
Sucampo Pharmaceuticals's current market capitalization is $680.1 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 89.6 m | 115.5 m | 153.2 m | 230.1 m |
Revenue growth, % | 29% | 33% | 50% | |
Cost of goods sold | 12.4 m | 16.3 m | 36.7 m | 76 m |
Gross profit | 77.2 m | 99.2 m | 116.4 m | 154.1 m |
Gross profit Margin, % | 86% | 86% | 76% | 67% |
R&D expense | 46.6 m | |||
General and administrative expense | 43.8 m | |||
Operating expense total | 68 m | 72 m | 72 m | 176.2 m |
EBIT | 9.2 m | 27.2 m | 44.5 m | 53.9 m |
EBIT margin, % | 10% | 24% | 29% | 23% |
Interest expense | 1.9 m | 1.5 m | 6.9 m | 23.8 m |
Interest income | 124 k | 172 k | 181 k | 72 k |
Pre tax profit | 10.3 m | 27.1 m | 43.7 m | 14.4 m |
Income tax expense | (3.9 m) | (14 m) | (10.3 m) | 4.1 m |
Net Income | 6.4 m | 13.1 m | 33.4 m | 18.5 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 44.1 m | 71.6 m | 108.3 m | 198.3 m |
Accounts Receivable | 5.4 m | 5.3 m | 22.8 m | 43 m |
Inventories | 4 m | 3.4 m | 8.9 m | 23.5 m |
Current Assets | 113.4 m | 122.3 m | 251.4 m | 307.2 m |
PP&E | 1.2 m | 763 k | 6.4 m | 6.2 m |
Goodwill | 60.9 m | 73 m | ||
Total Assets | 137 m | 141.6 m | 457.2 m | 520.9 m |
Accounts Payable | 7.6 m | 4.1 m | 11.2 m | 9.2 m |
Current Liabilities | 42.6 m | 33.8 m | 88.1 m | 32.4 m |
Total Liabilities | 353.8 m | |||
Additional Paid-in Capital | 72.1 m | 83.6 m | 99.2 m | 120.3 m |
Retained Earnings | (27.7 m) | (13.7 m) | 19.6 m | 38.1 m |
Total Equity | 58.1 m | 82.3 m | 86.4 m | 167.1 m |
Financial Leverage | 2.4 x | 1.7 x | 5.3 x | 3.1 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | 6.4 m | 13.1 m | 33.4 m | 18.5 m |
Depreciation and Amortization | 1.5 m | 10.6 m | 45.7 m | |
Accounts Receivable | (4 m) | (8.5 m) | (18.8 m) | |
Inventories | (163 k) | (1.4 m) | (1.2 m) | |
Accounts Payable | 2.2 m | (1.7 m) | (2.8 m) | |
Cash From Operating Activities | (5.4 m) | 27.5 m | 18.6 m | 8.3 m |
Purchases of PP&E | (168 k) | (3.6 m) | (1.2 m) | |
Cash From Investing Activities | (13.9 m) | (131.2 m) | (1.8 m) | |
Cash From Financing Activities | 10.6 m | 149.3 m | 70.5 m | |
Interest Paid | 156 k | 6 m | 20 m |
| Y, 2016 | |
|---|---|
Financial Leverage | 3.1 x |
